MalgorzataMcMastersMD

Oncology • Newton, MA

Hematologic Oncology

Physician

Join to view full profile

Dr. McMasters is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McMasters' full profile

Already have an account?

Office
NWH Cancer Center
2014 Washington Street
Newton, MA 02462
Phone+1 617-219-1230

Fax+1 617-831-7331

Education & Training

Westchester Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Zucker School of Medicine at Hofstra/Northwell at Lenox Hill HospitalResidency, Internal Medicine, 2003 - 2006
Medical University of SilesiaClass of 1995

Certifications & Licensure

MA State Medical License 2009 - 2026
NY State Medical License 2009 - 2011
NJ State Medical License 2009 - 2009
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2013 Nov 01
Completed
Phase 1
Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults Start of enrollment: 2014 Dec 01
Completed
Phase 1
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia Start of enrollment: 2016 Sep 01
Withdrawn
Phase 1
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML Start of enrollment: 2018 Jul 24
Recruiting
Phase 1
AZD6738 for Patients With Progressive MDS or CMML Start of enrollment: 2019 Aug 05
Recruiting
Phase 1
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Start of enrollment: 2018 Aug 15
Recruiting
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia.
Marlise R Luskin, Mark Alan Murakami, Julia H Keating, Yael Flamand, Eric S Winer
Blood. 2024-10-07
98 citations
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.
David P. Steensma, Martin Wermke, Virginia M. Klimek, Peter L. Greenberg, Patricia Font
Leukemia. 2021-06-25
3 citations
Casting a wider protective net: Anti-infective vaccine strategies for patients with hematologic malignancy and blood and marrow transplantation.
Malgorzata McMasters, Barbra M. Blair, Hillard M. Lazarus, Carolyn D. Alonso
Blood Reviews. 2021-05-01

Abstracts/Posters

A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older Adults
Malgorzata McMasters, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...
Malgorzata McMasters, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019